Concordia Healthcare Corp. (Nasdaq: CXRX) to Ring The Nasdaq Stock Market Opening Bell

ADVISORY, Aug. 11, 2015 (GLOBE NEWSWIRE) --

What: 

Concordia Healthcare Corp. (Nasdaq:CXRX), a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Mark Thompson, Chief Executive Officer, will ring the Opening Bell. 

Where:

Nasdaq MarketSite - 4 Times Square - 43^rd & Broadway - Broadcast Studio

When:

Wednesday, August 12, 2015 - 9:15 a.m. to 9:30 a.m. ET          

Concordia Healthcare Corp. Media Contact: 
Marija Mandic
905-842-5150 X240 
mmandic@concordiarx.com

Nasdaq MarketSite: 
Angela Tu
(646) 225-0316
Angela.Tu@nasdaq.com

Feed Information: 
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:

http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page:

http://instagram.com/nasdaq

For news tweets, please visit our Twitter page at:

http://twitter.com/nasdaq

For exciting viral content and ceremony photos visit Tumblr Page:

http://nasdaq.tumblr.com/

Webcast:
A webcast of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

About Concordia Healthcare Corp. (Nasdaq:CXRX):

Concordia is a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs. Concordia's legacy pharmaceutical division, Concordia Pharmaceuticals Inc., consists of a portfolio of branded products and authorized generic contracts, including branded products such as Nilandron®, for the treatment of metastatic prostate cancer; Dibenzyline®, for the treatment of pheochromocytoma; Lanoxin®, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil®, for the treatment of lupus and rheumatoid arthritis; Donnatal® for the treatment of irritable bowel syndrome; and Zonegran® (zonisamide) for treatment of partial seizures in adults with epilepsy. Concordia's orphan drugs division, Concordia Laboratories Inc., owns Photofrin®. Photofrin® is marketed by Pinnacle Biologics, Inc. in the United States.

Concordia operates out of facilities in Oakville, Ontario; Bridgetown, Barbados; Roanoke, Virginia and has a specialty healthcare distribution (SHD) division that operates out of Kansas City, Missouri. Pinnacle Biologics Inc. is located in Chicago, Illinois.

About Nasdaq:

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of approximately $9.6 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-

News Provided by Acquire Media